APOL6 and melanoma: After adjusting for clinical covariates, the upregulation of APOL6 remained a protective factor for improved response (the ORs (95%CI) were 12.46 (3.11, 50.01) and 2.08 (0.97, 4.46) for melanoma and urothelial cancer, respectively, as shown in Table 1 and Table S1).